Home » CELLDEX BUYS LORANTIS, ALTERIS
CELLDEX BUYS LORANTIS, ALTERIS
Celldex Therapeutics said on Wednesday it has acquired all the issued and outstanding shares of the British biotechnology company Lorantis, as well as the assets of Alteris Therapeutics. Medarex, an antibody-focused biotechnology company located in Princeton, New Jersey, will own approximately 60 percent of Celldex when the two acquisitions close. "The acquisition of Lorantis and the assets of Alteris bring important resources that we believe are complementary to Celldex's technology and that have the potential to enhance and broaden Celldex's development pipeline," said Celldex CEO Michael W. Fanger.
Red Herring (http://www.redherring.com/Article.aspx?a=13962&hed=Celldex%2BBuys%2BLorantis%2C%2BAlteris)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May